Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

An Investigation of CYP2D… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Kontaktformulär








 


OBS! Vill du ha svar, ange e-post eller telefonnummer!




An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure: A MERIT-HF Substudy

Artikel i vetenskaplig tidskrift
Författare J. A. Batty
A. S. Hall
H. L. White
John Wikstrand
R. A. de Boer
D. J. van Veldhuisen
P. van der Harst
Finn Waagstein
Åke Hjalmarson
J. Kjekshus
A. J. Balmforth
Publicerad i Clinical Pharmacology & Therapeutics
Volym 95
Nummer/häfte 3
Sidor 321-330
ISSN 0009-9236
Publiceringsår 2014
Publicerad vid Wallenberglaboratoriet
Sidor 321-330
Språk en
Länkar dx.doi.org/10.1038/clpt.2013.193
Ämnesord RANDOMIZED INTERVENTION TRIAL, CYTOCHROME-P450 2D6, ANKYLOSING-SPONDYLITIS, CLINICAL-OUTCOMES, ADVERSE EVENTS, BETA-BLOCKERS, TASK-FORCE, PHARMACOKINETICS, METABOLISM, OXIDATION
Ämneskategorier Klinisk farmakologi

Sammanfattning

To explore the pharmacogenetic effects of the cytochrome P450 (CYP) 2D6 genotype in patients with systolic heart failure treated using controlled/extended-release (CR/XL) metoprolol, this study assessed the CYP2D6 locus for the nonfunctional * 4 allele (1846G> A; rs3892097) in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF; n = 605). Participants were characterized as extensive, intermediate, or poor metabolizers (EMs, IMs, or PMs, respectively), based on the presence of the CYP2D6* 4 allele (EM: * 1* 1, 60.4%; IM: * 1* 4, 35.8%; and PM: * 4* 4, 3.8%). Plasma metoprolol concentrations were 2.1-/4.6-fold greater in the IM/PM groups as compared with the EM group (P < 0.0001). Metoprolol induced significantly lower heart rates and diastolic blood pressures during early titration, indicating a CYP2D6* 4 allele dose-response effect (P < 0.05). These effects were not observed at maximal dose, suggesting a saturable effect. Genotype did not adversely affect surrogate treatment efficacy. CYP2D6 genotype modulates metoprolol pharmacokinetics/pharmacodynamics during early titration; however, the MERIT-HF-defined titration schedule remains recommended for all patients, regardless of genotype.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?